Literature DB >> 15932551

Management of pilonidal sinus using fibrin glue: a new concept and preliminary experience.

M I Seleem1, A M Al-Hashemy.   

Abstract

BACKGROUND: There is a multiplicity of treatment techniques described for pilonidal sinus. However none of the methods has emerged as being superior to the others. A ideal treatment should be simple, lead to minimal disability and a rapid return to normal activity. We present the preliminary finding an operative technique using fibrin glue in patents with pilonidal sinus. PATIENTS AND METHODS: The study was carried out in the surgical unit of the Armed Forces Hospital, Khamis Mushayt, Kingdom of Saudi Arabia. From September 2001 to February 2004, 25 consecutive patients with primary pilonidal sinus, were prospectively submitted to tension free excision and fibrin glue injection under local anaesthesia as day surgery cases. There were 23 males and 2 females with a mean age of 26.4 years (range 17-50 years). The data recorded included the duration of the disease symptoms, operative time, duration of hospital stay, postoperative analgesia, and return to work. All excised specimens were sent to histopathology. The postoperative disability and the social disruption were evaluated by indirect questions about the ability to drive a car and the position assumed while at home in the outpatient follow-up.
RESULTS: The mean duration of the symptoms was 15.4 months (range 4-36 months). Mean operative time including local anaesthetic time was 19.3 min (range 15-50 min). The mean hospital stay was 7.5 h (range 6-10 h). All patients were discharged home on the day of surgery. Mean follow-up was 10.8 months (range 4-36 months). Primary healing was achieved in 24 (96%) patients within two weeks. One (4%) patient had a breakdown of the fibrin glue and the open wound managed with daily betadine dressings.
CONCLUSION: The management of pilonidal sinus with excision under local anesthesia and application of a fibrin glue is simple and reduces postoperative disability and disruption of patient social life.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15932551     DOI: 10.1111/j.1463-1318.2005.00808.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  7 in total

1.  The use of fibrin glue without surgery in the treatment of pilonidal sinus disease.

Authors:  Arda Isik; Ramazan Eryılmaz; Ismail Okan; Fatih Dasiran; Deniz Firat; Oguz Idiz; Mustafa Sahin
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  Fibrin glue is a quick and effective treatment for primary and recurrent pilonidal sinus disease.

Authors:  T S Sian; P J J Herrod; J E M Blackwell; E J O Hardy; J N Lund
Journal:  Tech Coloproctol       Date:  2018-11-09       Impact factor: 3.781

3.  Crystallized phenol treatment of pilonidal disease improves quality of life.

Authors:  Omer Topuz; Selim Sözen; Mustafa Tükenmez; Sezgin Topuz; Umit Erkan Vurdem
Journal:  Indian J Surg       Date:  2012-06-29       Impact factor: 0.656

4.  Fibrin sealant use in pilonidal sinus: Systematic review.

Authors:  Cuneyt Kayaalp; Ismail Ertugrul; Kerem Tolan; Fatih Sumer
Journal:  World J Gastrointest Surg       Date:  2016-03-27

5.  A Comparison between the Tie-over and Closed Suction Drainage Therapeutic Strategies in Patients Suffering from Sacral Pilonidal Sinus.

Authors:  Mojtaba Ahmadinejad; Koorosh Ahmadi; Izadmehr Ahmadinejad; Amir Masoud Hashemian; Peyman Khademhoseini
Journal:  Int J Biomed Sci       Date:  2016-12

6.  Common surgical procedures in pilonidal sinus disease: A meta-analysis, merged data analysis, and comprehensive study on recurrence.

Authors:  V K Stauffer; M M Luedi; P Kauf; M Schmid; M Diekmann; K Wieferich; B Schnüriger; D Doll
Journal:  Sci Rep       Date:  2018-02-15       Impact factor: 4.379

7.  Impact of geography and surgical approach on recurrence in global pilonidal sinus disease.

Authors:  Dietrich Doll; Andriu Orlik; Katharina Maier; Peter Kauf; Marco Schmid; Maja Diekmann; Andreas P Vogt; Verena K Stauffer; Markus M Luedi
Journal:  Sci Rep       Date:  2019-10-22       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.